Triple-combination therapy reduces COPD exacerbations

GlaxoSmithKline and Innoviva’s triple-combination therapy of fluticasone furoate, umeclidinium and vilanterol significantly reduced the amount of exacerbations experienced by patients with chronic obstructive pulmonary disease compared with AstraZeneca’s Symbicort Turbohaler, according to phase 3 study results presented at the 2016 European Respiratory Society International Congress. Results showed that patients in the triple-combination therapy group hadContinue reading “Triple-combination therapy reduces COPD exacerbations”

Statins in COPD: Useful or Not?

Statins were developed 3 decades ago to control blood cholesterol and its components, and thus reduce the risks for myocardial and other vascular events. That goal has been achieved successfully. With the widespread use of statins, it soon became clear that these drugs might have other actions, with anti-inflammatory action being one possibility. Some benefitContinue reading “Statins in COPD: Useful or Not?”

Benzodiazepines May Worsen Respiratory Outcomes in COPD

New use of benzodiazepines may increase the risk of adverse respiratory outcomes in older adults with chronic obstructive pulmonary disease (COPD), according to research published online April 17 in the European Respiratory Journal. Nicholas T. Vozoris, MD, of the University of Toronto, and colleagues conducted a retrospective population-based cohort study involving adults aged ≥66 yearsContinue reading “Benzodiazepines May Worsen Respiratory Outcomes in COPD”

CHMP Positive on Glaxo’s Two Drugs

GlaxoSmithKline announced that two chronic obstructive pulmonary disease COPD drugs Incruse and Anoro have received a positive opinion from the European Medicines Agency’s EMA Committee for Medicinal Products for Human Use CHMP. A final decision from the European Commission should be out by the end of the next quarter. Glaxo is looking to get IncruseContinue reading “CHMP Positive on Glaxo’s Two Drugs”